20/20 HealthCare Partners Collaborates with Roche to Source and Advance BioTech Innovations
May 28, 2014 – Auburndale, Mass. – 20/20 HealthCare Partners LLC (20/20 HCP), a global investment group focused on early stage medical technology and life science innovation, is pleased to announce an agreement with Roche, in which they will source and identify novel treatments and/or technologies in the biotech arena. These areas include oncology/immuno-oncology, neurology, infectious diseases, inflammation and ophthalmology. The partnership aims to advance any identified technologies by facilitating collaborations or the formation of new life science companies.
“Through our partnering with Roche, we hope to identify scientific innovations that could lead to novel treatments for patients, thus contributing to better management of serious disease conditions,” said Hillel Bachrach, Managing Partner, 20/20 HCP. “There is significant innovation coming from academia and other research organizations, and we can provide the experience of successfully moving along start-up companies and the capital resources necessary to help advance breakthrough treatments.”
To enhance its relationships with the targeted institutions and to aid in the successful formation of new life science companies, 20/20 HCP has contracted with pharmaceutical and life sciences industry professional Christine Bunt as a 20/20 HCP Venture Partner. Her extensive experience includes the formation and leadership of two life science companies, leading worldwide commercialization for treatments and holding R&D and business development roles with major pharmaceutical companies. Ms. Bunt will lead efforts and serve as a liaison between 20/20 HCP and Roche.
“Joining forces with 20/20 HCP and taking a lead role in the Roche partnership will enable me to leverage my background in advancing groundbreaking innovative treatments for patients,” said Ms. Bunt.